China's Pharmaceutical Market Situation And The Domestic Enterprise Development Strategy Study

Since China's entry into the WTO in 2001, world's top 30 transnational medicine corporations almost have landed China successfully all and established stable bases, and the wonderful expectations of revenue bring more investments, as well as local research and development. Within recent years, China government released much more medical industry standards even than the total amount of the past few decades and kept on regulating medical industry by administration methods to promote industry promotion. Lack of ability of R&D, capital and advanced administrational experiences, some China medicine corporations which are aware of these shortcomings starts merger and acquisition to protect self-development, while most of them have to march on harshly without any privileges. This is one of the most important studies that domestic medicine companies confront. This dissertation analyses the strength and weakness domestic companies have before the opportunities and challenges in international and domestic markets by picturing the inner and outer circumstances and comparing with the transnational companies which have invested in China based on the theory of Competition Advantage and the Eclectic of Paradigm of International Production. The last part of this dissertation offers suggestions in detail on the competition strategies to the Chinese medicine enterprises.